Advances in modeling and treating spinal muscular atrophy

Area of Science:

• Neuroscience
• Genetics
• Pediatric Neurology

Background:

• Spinal muscular atrophy (SMA) is an inherited childhood neurodegenerative disorder.
• It is caused by deficiency of the survival motor neuron (SMN) protein.
• Hallmarks include motor neuron loss and skeletal muscle atrophy.

Purpose of the Study:

• To highlight recent progress in understanding SMA pathology.
• To review the development of therapeutic approaches for SMA treatment.

Main Methods:

• Phenotypic characterization of SMA mouse models.
• Analysis of SMN restoration/depletion in controlled settings.
• Investigating SMN requirements during neuromuscular development.

Main Results:

• SMN deficiency impacts cells beyond motor neurons, both within and outside the nervous system.
• SMN has a higher demand during neuromuscular development.
• Preclinical development of gene therapy and splicing modulation approaches.

Conclusions:

• Understanding cell-specific SMN deficiency is crucial for SMA therapy.
• Identifying the therapeutic window for treatment is a key advance.
• SMN-upregulating drugs and novel therapies are progressing to human trials.